CO6290696A2 - Gel de fibrina para liberacion controlada de pdgf y usos del mismo - Google Patents

Gel de fibrina para liberacion controlada de pdgf y usos del mismo

Info

Publication number
CO6290696A2
CO6290696A2 CO10004831A CO10004831A CO6290696A2 CO 6290696 A2 CO6290696 A2 CO 6290696A2 CO 10004831 A CO10004831 A CO 10004831A CO 10004831 A CO10004831 A CO 10004831A CO 6290696 A2 CO6290696 A2 CO 6290696A2
Authority
CO
Colombia
Prior art keywords
pdgf
controlled release
fibrine
gel
same
Prior art date
Application number
CO10004831A
Other languages
English (en)
Spanish (es)
Inventor
Isabelle Catelas
Joseph Dwyer
Wanda Seyton
Shane Donovan
Sam L Helgerson
Original Assignee
Baxter Internac Inc
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Internac Inc, Baxter Healthcare Sa filed Critical Baxter Internac Inc
Publication of CO6290696A2 publication Critical patent/CO6290696A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
CO10004831A 2007-06-19 2010-01-19 Gel de fibrina para liberacion controlada de pdgf y usos del mismo CO6290696A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93619807P 2007-06-19 2007-06-19

Publications (1)

Publication Number Publication Date
CO6290696A2 true CO6290696A2 (es) 2011-06-20

Family

ID=39760930

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10004831A CO6290696A2 (es) 2007-06-19 2010-01-19 Gel de fibrina para liberacion controlada de pdgf y usos del mismo

Country Status (12)

Country Link
US (2) US8377864B2 (https=)
EP (1) EP2167114A2 (https=)
JP (2) JP2010530882A (https=)
KR (2) KR101399677B1 (https=)
CN (1) CN101772350A (https=)
AU (1) AU2008265637B2 (https=)
BR (1) BRPI0812718A2 (https=)
CA (1) CA2691024A1 (https=)
CO (1) CO6290696A2 (https=)
IL (1) IL202800A0 (https=)
MX (1) MX2009013970A (https=)
WO (1) WO2008157733A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0812718A2 (pt) * 2007-06-19 2014-12-23 Baxter Int Métodos para modificar a liberação de uma proteína do fator de crescimento derivado de plaqueta, para modificar a liberação de um fator de crescimento derivado de plaqueta, para a liberação de uma proteína do fator de crescimento derivado de plaqueta e para tratar um paciente que sobre de um distúrbio ou doença, kit, e, uso de um selante de fibrina
JP5869219B2 (ja) 2007-08-16 2016-02-24 レメドー バイオメッド リミテッド 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
US20100310626A1 (en) * 2008-01-24 2010-12-09 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
EP2282746B8 (en) * 2008-03-27 2015-12-09 Caladrius Biosciences, Inc. Compositions and methods using stem cells in cutaneous wound healing
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
CA2772084C (en) * 2009-08-27 2016-10-18 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
US20110200577A1 (en) * 2010-01-08 2011-08-18 Baxter International Inc. Biomatrices to attract and retain regenerative and reparative cells
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
AU2011296356B2 (en) 2010-09-03 2015-07-09 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
CN103230589B (zh) * 2013-04-25 2015-01-14 上海神因生物科技有限公司 一种纤维蛋白原复合物及其应用
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
CN104004709B (zh) * 2014-05-05 2016-05-18 曾奕明 用于促进人胚肺成纤维细胞增殖分化的多种生长因子复合物纤维蛋白凝胶释放系统
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
CN104548212B (zh) * 2014-12-31 2018-05-11 新科沃再生医学（苏州）有限公司 一种促进牙髓及牙本质再生的组合物
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
KR102171433B1 (ko) * 2018-05-25 2020-11-02 고려대학교 산학협력단 조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법
WO2019237157A1 (en) * 2018-06-14 2019-12-19 The University Of Sydney Cardiac treatment
US12252582B2 (en) 2019-08-29 2025-03-18 University Of Delaware Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
CN113735979A (zh) * 2021-07-15 2021-12-03 吉林大学 一种重组人血小板衍生因子（rhPDGF-BB）-Fc融合蛋白及其使用
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
CA2097063C (en) 1990-11-27 2006-08-08 Howard P. Greisler Tissue sealant and growth factor containing compositions that promote accelerated wound healing
US5792835A (en) 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
US6965014B1 (en) * 1996-01-16 2005-11-15 Baxter International Inc. Fibrin material and method for producing and using the same
WO1996040174A1 (en) 1995-06-07 1996-12-19 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
DE19617369A1 (de) 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
AT406120B (de) 1997-08-28 2000-02-25 Immuno Ag Gewebekleber
CA2362513C (en) 1999-02-12 2011-04-26 Baxter Aktiengesellschaft A method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method
US6696073B2 (en) 1999-02-23 2004-02-24 Osteotech, Inc. Shaped load-bearing osteoimplant and methods of making same
US6506365B1 (en) 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
CA2442855A1 (en) 2001-04-12 2002-10-24 Therics, Inc. Method and apparatus for engineered regenerative biostructures
EP1406678B1 (en) * 2001-04-25 2009-01-14 Eidgenössische Technische Hochschule Zürich Drug delivery matrices to enhance wound healing
AU2002343738A1 (en) * 2001-11-15 2003-05-26 University Of Medicine And Dentistry Of New Jersey A three-dimensional matrix for producing living tissue equivalents
US20050064042A1 (en) * 2003-04-29 2005-03-24 Musculoskeletal Transplant Foundation Cartilage implant plug with fibrin glue and method for implantation
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
BRPI0812718A2 (pt) * 2007-06-19 2014-12-23 Baxter Int Métodos para modificar a liberação de uma proteína do fator de crescimento derivado de plaqueta, para modificar a liberação de um fator de crescimento derivado de plaqueta, para a liberação de uma proteína do fator de crescimento derivado de plaqueta e para tratar um paciente que sobre de um distúrbio ou doença, kit, e, uso de um selante de fibrina

Also Published As

Publication number Publication date
KR20100047227A (ko) 2010-05-07
CN101772350A (zh) 2010-07-07
IL202800A0 (en) 2011-08-01
JP2014138907A (ja) 2014-07-31
US20130143808A1 (en) 2013-06-06
EP2167114A2 (en) 2010-03-31
JP2010530882A (ja) 2010-09-16
KR20110138302A (ko) 2011-12-26
CA2691024A1 (en) 2008-12-24
AU2008265637A1 (en) 2008-12-24
US20090075881A1 (en) 2009-03-19
US8377864B2 (en) 2013-02-19
WO2008157733A3 (en) 2009-11-12
WO2008157733A2 (en) 2008-12-24
MX2009013970A (es) 2010-09-10
KR101399677B1 (ko) 2014-06-19
AU2008265637B2 (en) 2014-04-17
BRPI0812718A2 (pt) 2014-12-23
US9012393B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
CO6290696A2 (es) Gel de fibrina para liberacion controlada de pdgf y usos del mismo
JP2010530882A5 (https=)
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
WO2009134991A3 (en) Tissue engineered blood vessel
EA017150B9 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
MX354144B (es) Metodo, fabricacion y uso de productos medicos que liberan sustancia activa para mantener vasos sanguineos abiertos.
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
CL2008003848A1 (es) Compuestos derivados de fenilo o heteroarilo bis-sulfonilamino sustituidos, inhibidores de prostaglandina e sintasa-1 microsomal; composicion farmaceutica; procedimiento de preparacion; procedimiento de preparacion de la composicion farmaceutica; y uso en el tratamiento del dolor agudo o cronico, dolor nociceptivo o dolor neuropatico.
EA201170349A1 (ru) Модуляторы mif
CO6620068A2 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi)
MX2013003282A (es) Materiales y metodos para mejorar la funcion gastrointestinal.
MY151159A (en) 5-lipoxygenase-activating protien (flap) inhibitors
WO2007141278A3 (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
PH12012502460A1 (en) Thioacetate compounds, compositions and methods of use
EA200870593A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
RU2009118942A (ru) Способ стимуляции регенерации тканей
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
CO6531414A2 (es) Aptámeros del inhibidor de la vía del factor tisular y sus usos como tratamiento de trastornos hemorrágicos
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
CL2010000829A1 (es) Metodo para tratar plantas que comprende aplicar a las plantas una composicion liquida que contiene ente 0,3 a 300 miligramos de uno o mas ciclopropenos por litro de dicha composicion.
CO6400200A2 (es) Preparaciones basadas en fibrinógeno y polisacáridos sulfatados

Legal Events

Date Code Title Description
FC Application refused